116 related articles for article (PubMed ID: 36519916)
1. Immunological and Clinico-Molecular Features of Tumor Border Configuration in Colorectal Cancer.
Sonal S; Deshpande V; Ting DT; Neyaz A; Pankaj A; Taylor MS; Dinaux AM; Leijssen LG; Boudreau C; Berger DL
J Am Coll Surg; 2023 Jan; 236(1):126-134. PubMed ID: 36519916
[TBL] [Abstract][Full Text] [Related]
2. Molecular Basis of Extramural Vascular Invasion (EMVI) in Colorectal Carcinoma.
Sonal S; Deshpande V; Ting DT; Cusack JC; Parikh AR; Neyaz A; Pankaj A; Taylor MS; Dinaux AM; Leijssen LGJ; Boudreau C; Locascio JJ; Kunitake H; Goldstone RN; Bordeianou LG; Cauley CE; Ricciardi R; Berger DL
Ann Surg Oncol; 2022 Nov; 29(12):7372-7382. PubMed ID: 35917013
[TBL] [Abstract][Full Text] [Related]
3. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients.
Frey DM; Droeser RA; Viehl CT; Zlobec I; Lugli A; Zingg U; Oertli D; Kettelhack C; Terracciano L; Tornillo L
Int J Cancer; 2010 Jun; 126(11):2635-43. PubMed ID: 19856313
[TBL] [Abstract][Full Text] [Related]
4. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
[TBL] [Abstract][Full Text] [Related]
5. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
[TBL] [Abstract][Full Text] [Related]
7. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
8. Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right-sided and left-sided colorectal cancer.
Kanno H; Miyoshi H; Yoshida N; Sudo T; Nakashima K; Takeuchi M; Nomura Y; Seto M; Hisaka T; Tanaka H; Okuda K; Akagi Y; Ohshima K
Cancer Sci; 2020 Aug; 111(8):3032-3044. PubMed ID: 32449240
[TBL] [Abstract][Full Text] [Related]
9. Correlation of clinical, pathologic, and genetic parameters with intratumoral immune milieu in mucinous adenocarcinoma of the colon.
Neyaz A; Pankaj A; Crabbe A; Rickelt S; Leijssen L; Dinaux A; Taylor M; Shroff SG; Crotty R; Zhang ML; Yilmaz OH; Yılmaz O; Patil DT; Parikh AR; Ting DT; Berger D; Deshpande V
Mod Pathol; 2022 Nov; 35(11):1723-1731. PubMed ID: 35590108
[TBL] [Abstract][Full Text] [Related]
10. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
[TBL] [Abstract][Full Text] [Related]
11. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
[TBL] [Abstract][Full Text] [Related]
12. Clinical, pathological, genetics and intratumoural immune milieu of micropapillary carcinoma of the colon.
Deshpande V; Lee SH; Crabbe A; Pankaj A; Neyaz A; Ono Y; Rickelt S; Sonal S; Ferrone CR; Ting DT; Patil D; Yilmaz O; Berger D; Yilmaz O
J Clin Pathol; 2024 May; 77(6):387-393. PubMed ID: 37258254
[TBL] [Abstract][Full Text] [Related]
13. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas.
Le Gouvello S; Bastuji-Garin S; Aloulou N; Mansour H; Chaumette MT; Berrehar F; Seikour A; Charachon A; Karoui M; Leroy K; Farcet JP; Sobhani I
Gut; 2008 Jun; 57(6):772-9. PubMed ID: 17965063
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status.
Koelzer VH; Baker K; Kassahn D; Baumhoer D; Zlobec I
J Clin Pathol; 2012 Nov; 65(11):996-1002. PubMed ID: 22859396
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
[TBL] [Abstract][Full Text] [Related]
17. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
[TBL] [Abstract][Full Text] [Related]
18. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.
Toon CW; Chou A; DeSilva K; Chan J; Patterson J; Clarkson A; Sioson L; Jankova L; Gill AJ
Mod Pathol; 2014 May; 27(5):644-50. PubMed ID: 24157612
[TBL] [Abstract][Full Text] [Related]
19. Clinical, pathological genetics and intratumoral immune milieu of serrated adenocarcinoma of the colon.
Yılmaz O; Crabbe A; Neyaz A; Pankaj A; Lee SH; Hosseini S; Rickelt S; Cerda S; Zhao Q; Leijsen L; Dineaux A; Shroff SG; Crotty R; Zhang ML; Yilmaz OH; Patil DT; Berger D; Deshpande V
Histopathology; 2022 Sep; 81(3):380-388. PubMed ID: 35789111
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory receptor CD94/NKG2A on CD8
Eugène J; Jouand N; Ducoin K; Dansette D; Oger R; Deleine C; Leveque E; Meurette G; Podevin J; Matysiak T; Bennouna J; Bezieau S; Volteau C; Thomas WEA; Chetritt J; Kerdraon O; Fourquier P; Thibaudeau E; Dumont F; Mosnier JF; Toquet C; Jarry A; Gervois N; Bossard C
Mod Pathol; 2020 Mar; 33(3):468-482. PubMed ID: 31409873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
